Treatment of rheumatoid arthritis with selective costimulation modulator abatacept - Twelve-month results of a phase-IIb, double-blind, randomised, placebo-controlled trial (vol 52, pg 2263, 2005)

被引：0
|
作者：
Kremer, JM
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3321 / 3321
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of meloxicam in the treatment of rheumatoid arthritis (RA): Results of a phase III double-blind, placebo controlled trial.
    Furst, DE
    Hall, DB
    Roszko, PJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S225 - S225
  • [32] Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
    Brunner, Hermine, I
    Foeldvari, Ivan
    Alexeeva, Ekaterina
    Ayaz, Nuray Aktay
    Calvo Penades, Inmaculada
    Kasapcopur, Ozgur
    Chasnyk, Vyacheslav G.
    Hufnagel, Markus
    Zuber, Zbigniew
    Schulert, Grant
    Ozen, Seza
    Rakhimyanova, Adelina
    Ramanan, Athimalaipet
    Scott, Christiaan
    Sozeri, Betul
    Zholobova, Elena
    Martin, Ruvie
    Zhu, Xuan
    Whelan, Sarah
    Pricop, Luminita
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01) : 154 - 160
  • [33] Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
    van Vollenhoven, Ronald F.
    Keystone, Edward Clark
    Strand, Vibeke
    Pacheco-Tena, Cesar
    Vencovsky, Jiri
    Behrens, Frank
    Racewicz, Arthur
    Zipp, Daniela
    Rharbaoui, Faiza
    Wolter, Ralf
    Knierim, Luise
    Schmeidl, Rainer
    Zhou, Xuefei
    Aigner, Silke
    Daelken, Benjamin
    Wartenberg-Demand, Andrea
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 495 - 499
  • [34] Oral type II collagen treatment in early rheumatoid arthritis - A double-blind, placebo-controlled, randomized trial
    Sieper, J
    Kary, S
    Sorensen, H
    Alten, R
    Eggens, U
    Huge, W
    Hiepe, F
    Kuhne, A
    Listing, J
    Ulbrich, N
    Braun, J
    Zink, A
    Mitchison, NA
    ARTHRITIS AND RHEUMATISM, 1996, 39 (01): : 41 - 51
  • [35] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10410): : 1328 - 1328
  • [36] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10404): : 774 - 774
  • [37] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (vol 392, pg 222, 2018)
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    LANCET, 2018, 392 (10146): : 476 - 476
  • [38] A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
    Alton, Eric W. F. W.
    Boyd, A. Christopher
    Cheng, Seng H.
    Cunningham, Steve
    Davies, Jane C.
    Gill, Deborah R.
    Griesenbach, Uta
    Higgins, Tracy
    Hyde, Stephen C.
    Innes, J. Alastair
    Murray, Gordon D.
    Porteous, David J.
    THORAX, 2013, 68 (11) : 1075 - 1077
  • [39] Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomised, placebo-controlled trial
    Reginster, J-Y
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) : E8 - E8
  • [40] Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial
    Kemp, William
    Colman, John
    Thompson, Kenneth
    Madan, Anoop
    Vincent, Margaret
    Chin-Dusting, Jaye
    Kompa, Andrew
    Krum, Henry
    Roberts, Stuart
    LIVER INTERNATIONAL, 2009, 29 (03) : 427 - 433
12345